Viewing Study NCT02517892


Ignite Creation Date: 2025-12-24 @ 3:24 PM
Ignite Modification Date: 2026-02-21 @ 6:24 AM
Study NCT ID: NCT02517892
Status: COMPLETED
Last Update Posted: 2025-06-24
First Post: 2015-08-03
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Organization:

Study Overview

Official Title: A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents
Status: COMPLETED
Status Verified Date: 2025-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: MATCH-R
Brief Summary: This is a prospective study to identify molecular mechanisms of acquired resistance to targeted therapies in patients with unresectable or metastatic cancer.

This is a protocol to study clinical characteristics and biopsy tissue of patients with oncogene-driven cancer who have had previous clinical response to targeted therapy and subsequently experience progression of disease. The tissues and other specimens will be used to carry out laboratory studies to explore the molecular basis of acquired resistance to targeted therapies.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2014/2144 OTHER CSET number View